非酒精性脂肪肝早期階段通常不會對身體造成任何傷害，但如果情況持續，可能會導致嚴重的肝臟損傷，包括肝硬化。
許多營養補充劑在減緩NAFLD方面效果顯著。
維他命E：
患有脂肪肝疾病的人血液中的維他命E水平通常會降低，這是氧化作用增加所導致的結果（Bell et al 1992，Bahcecioglu et al 2005）。臨床研究明確支持每天使用800-1,200國際單位的維他命E能預防和治療NAFLD。
歐米茄-3脂肪酸：
歐米茄-3脂肪酸可以解決肝臟脂毒性問題，同時還能提供相當的抗炎活性（Perez-Martinez 2010）。
一項長期的人體試驗顯示，每天使用1000毫克 omega-3，肝細胞損傷、甘油三酯水平和空腹血糖的血清標誌物均有顯著降低。
S-腺苷甲硫氨酸（SAMe）：
穀胱甘肽（GSH）是一種天然抗氧化劑，參與許多肝臟解毒反應。 SAMe營養素可以補充GSH水平，並恢復對肝細胞的保護作用（Oz et al 2006）。每天補充1,200毫克 SAMe能有效增加肝臟穀胱甘肽水平（Vendemiale et al 1989）。
SAMe和其他肝臟抗氧化劑能夠改善肝酵素水平，這是肝臟細胞受損的早期標誌物（Chang et al 2006）。
N-乙酰半胱氨酸（NAC）：
另一種有效補充天然抗氧化劑穀胱甘肽的分子是N-乙酰半胱氨酸（NAC）。
在動物研究中，NAC能刺激已移除部分肝臟的動物的肝細胞再生（Uzun等2009）。
水飛薊素（奶薊）：
奶薊提取物長期以來一直用於保護肝臟。其有效成分水飛薊素具有優異的抗氧化和抗炎活性（Schrieber et al 2008，Feher等2008）。
Nutritional and Supplemental Support
Non-alcoholic fatty liver disease (NAFLD) is the term for a range of conditions caused by a build-up of fat in the liver. It's usually seen in people who are overweight or obese.
Early-stage NAFLD doesn't usually cause any harm, but it can lead to serious liver damage, including cirrhosis, if it gets worse.
Numerous nutritional approaches show real promise in slowing the development and progression of NAFLD.
Vitamin E:
People with fatty liver disease have depressed levels of vitamin E in their blood, the result of increased oxidation (Bell et al 1992, Bahcecioglu et al 2005). Clinical studies clearly support daily use of 800-1,200 IU of vitamin E for prevention and treatment of NAFLD.
Omega-3 Fatty Acids:
The omega-3 fatty acids attack the problem of lipotoxicity, while contributing considerable anti-inflammatory activity of their own (Perez-Martinez 2010).
A long-term human trial, using 1,000 mg per day of omega-3, revealed significant decreases in serum markers of liver cell damage, triglyceride levels, and fasting glucose.
S-Adenosylmethionine (SAMe):
Glutathione (GSH) is a natural antioxidant that participates in many liver detoxification reactions. The nutrient SAMe can replenish GSH levels and restore liver cell protection to normal (Oz et al 2006). Supplementation with 1,200 mg SAMe daily increased liver glutathione levels (Vendemiale et al 1989).
SAMe and other liver antioxidants improve levels of liver enzymes, an early marker of cell damage (Chang et al 2006).
N-Acetyl Cysteine (NAC):
Another molecule that supports and replenishes the natural antioxidant glutathione is N-acetyl cysteine (NAC).
In animal studies, NAC stimulates regeneration of healthy liver cells in animals that have part of their livers removed (Uzun et al 2009).
Silymarin (Milk Thistle):
Extracts of milk thistle have long been used for liver protection. Silymarin have exceptional antioxidant and anti-inflammatory activity (Schrieber et al 2008, Feher et al 2008).
1 Bell H, Bjorneboe A, Eidsvoll B, et al. Reduced concentration of hepatic alpha-tocopherol in patients with alcoholic liver cirrhosis. Alcohol Alcohol. 1992 Jan;27(1):39-46.
2 Bahcecioglu IH, Yalniz M, Ilhan N, Ataseven H, Ozercan IH. Levels of serum vitamin A, alpha-tocopherol and malondialdehyde in patients with nonalcoholic steatohepatitis: relationship with histopathologic severity. Int J Clin Pract. 2005 Mar;59(3):318-23.
3 Perez-Martinez P, Perez-Jimenez F, Lopez-Miranda J. n-3 PUFA and lipotoxicity. Biochim Biophys Acta. 2010 Mar;1801(3):362-6.
4 Oz HS, Im HJ, Chen TS, de Villiers WJ, McClain CJ. Glutathione-enhancing agents protect against steatohepatitis in a dietary model. J Biochem Mol Toxicol. 2006;20(1):39-47.
5 Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol. 1989 May;24(4):407-15.
6 Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH. Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S51-60.
7 Uzun MA, Koksal N, Kadioglu H, et al. Effects of N-acetylcysteine on regeneration following partial hepatectomy in rats with nonalcoholic fatty liver disease. Surg Today. 2009;39(7):592-7.
8 Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos. 2008 Sep;36(9):1909-16.
9 Feher J, Lengyel G. Silymarin in the treatment of chronic liver diseases: past and future. Orv Hetil. 2008 Dec 21;149(51):2413-8.
No comments:
Post a Comment